In the past year, Gilead Sciences has won approval of a gene therapy that rewrites cells from a patient's immune system so that they can track down and destroy cancer cells, while Spark Therapeutics has won approval for a therapy that restores vision by inserting a new functioning gene in people who are blind because of a rare genetic mutation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,